Effect of Mirtazapine on the quality of life of the breast cancer patients

Phase 3

Recruiting

• Conditions: Condition 1: breast cancer. Condition 2: Major depressive disorder.; Malignant neoplasm of breast; Major depressive disorder, single episode

• Registration Number: IRCT20210425051075N1
• Lead Sponsor: Sabzevar University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

Suffering from cancer
Major depressive disorder according to DSM IV criteria

Exclusion Criteria

Taking sleeping pills at the same time

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Quality of Life. Timepoint: Study first and 8 weeks after starting mirtazapine. Method of measurement: WHO Quality of Life Questionnaire.;Anxiety. Timepoint: Study first and 8 weeks after starting mirtazapine. Method of measurement: WHO Quality of Life Questionnaire.;Sleep status. Timepoint: Study first and 8 weeks after starting mirtazapine. Method of measurement: WHO Quality of Life Questionnaire.;Appetite status. Timepoint: Study first and 8 weeks after starting mirtazapine. Method of measurement: WHO Quality of Life Questionnaire.